TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30861455

Group type: EXPERIMENTAL
Intervention: DYNAMIC-ICU prediction rule
Number of subjects: 560
Study: 31126299

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks in rs9930506 risk allele carriers
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks in AA genotype carriers
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 18 weeks in AG/GG genotype carriers
Number of subjects: 62
Study: 28089180

Group type: EXPERIMENTAL
Intervention: Plain aspirin (325 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PL2200 (modified-release lipid-based aspirin, 325 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Delayed-release enteric-coated (EC) aspirin (325 mg)
Number of subjects: 40
Study: 25480541

Group type: EXPERIMENTAL
Intervention: Compliant prosthetic feet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Compliant and Intermediate prosthetic feet
Number of subjects: 11

Group type: COMPARATOR
Intervention: All prosthetic feet
Number of subjects: 11
Study: 24307825

Group type: EXPERIMENTAL
Intervention: New Brush Group (changed toothbrush every month)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Old Brush Group (used single toothbrush for the whole period of the study)
Number of subjects: 36
Study: 21199966

Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT) for 3 weeks, 1-hour early-morning exposure to pale blue light at approximately 7500 lux
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (dim red light, approximately 50 lux)
Number of subjects: 89
Study: 19595483

Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablets (30mg for 3 days)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lansoprazole capsules (30mg for 3 days)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Willingness to pay for orally disintegrating tablets
Number of subjects: 126
Study: 16888641

Group type: EXPERIMENTAL
Intervention: Wiped clean method
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control lenses (not cleaned)
Number of subjects: 25
Study: 14505239

Group type: EXPERIMENTAL
Intervention: Stoppa procedure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bilateral Lichtenstein procedure
Number of subjects: 45
Study: 11890485

Group type: EXPERIMENTAL
Intervention: 2-year support program based on nurse case management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 100
Study: 9513102

Group type: EXPERIMENTAL
Intervention: Soft stabilizing appliance
Number of subjects: 23

Group type: COMPARATOR
Intervention: Hard stabilizing appliance
Number of subjects: 23
Study: 7995806

Group type: EXPERIMENTAL
Intervention: Interactive video with differing realism conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional values of objectivity and authenticity
Number of subjects: 0
Study: 3142979

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 55
Study: 29763623

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) in addition to temozolomide/radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (temozolomide/radiotherapy without BEV)
Number of subjects: 0
Study: 26170014

Group type: EXPERIMENTAL
Intervention: Oral iron intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 23548532

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no add-on)
Number of subjects: 60
Study: 21667899

Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 169

Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 169
Study: 17999080

Group type: EXPERIMENTAL
Intervention: 200‐mg/day doxycycline for 4‐6 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 16837718

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Iron plus zinc supplementation
Number of subjects: 855
Study: 12765924

Group type: EXPERIMENTAL
Intervention: Aerochamber (AC) with 200 micro g budesonide twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nebuchamber (NC) with 200 micro g budesonide twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (baseline measurement)
Number of subjects: 30
Study: 10840911

Group type: EXPERIMENTAL
Intervention: Deceptive packaging design
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-deceptive packaging design
Number of subjects: 40
Study: 9124243

Group type: COMPARATOR
Intervention: Topical timolol maleate 0.5%
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Topical carteolol hydrochloride 1%
Number of subjects: 169

Group type: COMPARATOR
Intervention: Overall cardiovascular adverse effects
Number of subjects: 169
Study: 8267038

Group type: EXPERIMENTAL
Intervention: Prednisone plus low-dose aspirin (n = 12)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Aspirin alone (n = 22)
Number of subjects: 39
Study: 7468550

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Quinacrine
Number of subjects: 45
Study: 31397133

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needle-knife with precise three-dimensional stereotactic localization of ashi points
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ultrasound-guided intrathecal injection (control group)
Number of subjects: 74
Study: 27862108

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (CBT4BN)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Traditional face-to-face group cognitive-behavioral therapy (CBTF2F)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 191
Study: 25932697

Group type: EXPERIMENTAL
Intervention: Intensive peer coaching and nurse case management (PC-NCM)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intensive peer coaching (PC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 600
Study: 23324964

Group type: EXPERIMENTAL
Intervention: TCP (Ultraporous β-tricalcium phosphate)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TCP/BM (Ultraporous β-tricalcium phosphate combined with bone marrow aspirate)
Number of subjects: 55
Study: 21262857

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 19328598

Group type: EXPERIMENTAL
Intervention: Practidose individualised dispensing and dosing pillbox system
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 220
Study: 16603337

Group type: EXPERIMENTAL
Intervention: Parent-implemented Reciprocal Imitation Training (RIT), implemented twice a week for 10 weeks.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Parent-implemented RIT targeting object imitation.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Parent-implemented RIT targeting both object and gesture imitation.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Generalization assessed in families' homes at the end of treatment and a 1-month follow-up.
Number of subjects: 3
Study: 16827430

Group type: EXPERIMENTAL
Intervention: Hypervolemic hypertensive hemodilution (3H-therapy)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no 3H-therapy)
Number of subjects: 54
Study: 12662378

Group type: EXPERIMENTAL
Intervention: Lafutidine (20 mg twice daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg twice daily)
Number of subjects: 122
Study: 10511770

Group type: EXPERIMENTAL
Intervention: Group 2 patients (renal insufficiency)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: DD genotype of ACE gene
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combined analysis of ACE-DD and AGT-TT genotypes
Number of subjects: 53

Group type: COMPARATOR
Intervention: Group 1 patients (normal renal function)
Number of subjects: 53
Study: 7556745

Group type: EXPERIMENTAL
Intervention: levobunolol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 33
Study: 1706207

Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deoxycoformycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorodeoxyadenosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granulocyte colony stimulating factor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alkylating agents or intensive chemotherapy
Number of subjects: 0
Study: 6124236

Group type: EXPERIMENTAL
Intervention: Systematic desensitization
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adapted version of the Masters and Johnson method
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined treatment (desensitization followed by Masters and Johnson)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31771991

Group type: EXPERIMENTAL
Intervention: Mobile low-dose CT screening unit
Number of subjects: 550
Study: 30414600

Group type: EXPERIMENTAL
Intervention: Fundal dominant contractions (F dominance)
Number of subjects: 224
Study: 28691473

Group type: EXPERIMENTAL
Intervention: Bacteriotherapy (Lactobacillus Reuteri DSM 17938 and Lactobaciullus Reuteri ATCC PTA 5289)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 80
Study: 25741580

Group type: EXPERIMENTAL
Intervention: Probiotic-containing lozenges
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 30
Study: 23446957

Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: amlodipine 5 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg
Number of subjects: 88
Study: 21144753

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) exposure for five consecutive days
Number of subjects: 26

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 26
Study: 18037544

Group type: EXPERIMENTAL
Intervention: 10 microg vaccine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 5 microg vaccine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.5 microg vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Four low doses of 2.5 microg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Four low doses of 5 microg
Number of subjects: 48
Study: 17172187

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 (2 cp bid for ten days in a month) followed by Bifidobacterium longum W11 (one granulated suspension for 6 days on alternate weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rifaximin 200 (2 cp bid for ten days in a month)
Number of subjects: 70
Study: 14519566

Group type: EXPERIMENTAL
Intervention: Uncomplicated epilepsy group
Number of subjects: 440

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 440
Study: 10765078

Group type: EXPERIMENTAL
Intervention: Percent free prostate-specific antigen (PSA)
Number of subjects: 257
Study: 9206199

Group type: EXPERIMENTAL
Intervention: Anti-lipid A of LPS antibody (anti-LPS treatment group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 19
Study: 1728077

Group type: EXPERIMENTAL
Intervention: Ranitidine (100 mg intravenously every 12 hours for 72 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6383045

Group type: EXPERIMENTAL
Intervention: Ritodrine, 120 mg daily (oral)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Terbutaline, 30 mg daily (oral)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Terbutaline (oral)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ritodrine (oral)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ritodrine (intravenous)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Terbutaline (intravenous)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Terbutaline (serum glucose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ritodrine (serum glucose)
Number of subjects: 100
Study: 30226299

Group type: EXPERIMENTAL
Intervention: Physical exercise during the first 2 hours of hemodialysis sessions
Number of subjects: 69

Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 69
Study: 29959722

Group type: EXPERIMENTAL
Intervention: NIDA Standard education intervention
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: NIDA Standard plus motivational interviewing (MI-HIV)
Number of subjects: 400
Study: 26930488

Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Internet-delivered Cognitive Behavior Therapy (TA-ICBT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TA-ICBT
Number of subjects: 50
Study: 24290850

Group type: EXPERIMENTAL
Intervention: cVEMP (ipsilateral i-p13/n23 and contralateral c-n12/p24/n30)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oVEMP (contralateral c-n10/p16/n21 and ipsilateral i-n13)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SCD patient responses
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: cVEMP potentials
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oVEMP c-n10, p16 and n21 potentials
Number of subjects: 16
Study: 22918303

Group type: EXPERIMENTAL
Intervention: Baseline GDF‐15 concentration
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Changes in GDF‐15 from baseline to 4 years
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Baseline GDF‐15
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Baseline GDF‐15 after multivariate adjustment
Number of subjects: 496
Study: 21051772

Group type: EXPERIMENTAL
Intervention: Fall prevention intervention
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 543
Study: 17484003

Group type: EXPERIMENTAL
Intervention: BRAVO catheter‐free pH monitoring
Number of subjects: 133

Group type: COMPARATOR
Intervention: Conventional 24‐h pH monitoring
Number of subjects: 133
Study: 15789585

Group type: EXPERIMENTAL
Intervention: Free breathing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audio instruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined motion measurements for all patients
Number of subjects: 60
Study: 11181239

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at a mean flow rate of 1.3 +/- 0.4 l/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air administered at the same flow rate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 10
Study: 10771881

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus dexamethasone i.v.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Ceftriaxone alone
Number of subjects: 77
Study: 7910230

Group type: EXPERIMENTAL
Intervention: Standard treatment with PSK (protein‐bound polysaccharide)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard treatment alone (mitomycin plus oral fluorouracil)
Number of subjects: 262
Study: 2967433

Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole combination (330 mg-75 mg) given three times daily, with intravenous dipyridamole at 10 mg per hour for 24 hours before PTCA.
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole combination (active drug)
Number of subjects: 376
Study: 31959416

Group type: EXPERIMENTAL
Intervention: Plasmapheresis and aggressive fluid resuscitation
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Insulin and heparin treatment with aggressive fluid resuscitation
Number of subjects: 495

Group type: COMPARATOR
Intervention: Aggressive fluid resuscitation
Number of subjects: 495
Study: 29369834

Group type: EXPERIMENTAL
Intervention: Oral 3% hypertonic saline (HTS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IV 3% hypertonic saline (HTS)
Number of subjects: 20
Study: 27240822

Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis
Number of subjects: 86

Group type: COMPARATOR
Intervention: Straight anastomosis
Number of subjects: 86
Study: 26220439

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Habit reversal training (HRT)
Number of subjects: 60
Study: 23897332

Group type: EXPERIMENTAL
Intervention: Lidocaine in infiltration solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (infiltration solution without lidocaine)
Number of subjects: 0
Study: 19952802

Group type: EXPERIMENTAL
Intervention: Collaborative intervention for chronic pain
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 401
Study: 18266204

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention for CRC screening (2003)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Discussion of CRC with a doctor
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Reporting barriers to CRC screening
Number of subjects: 980
Study: 16507188

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 208
Study: 14620619

Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus bovine lactoferrin (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard triple therapy (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 10-day standard triple therapy (group C)
Number of subjects: 150
Study: 10489003

Group type: EXPERIMENTAL
Intervention: Continuous test protocol (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Separate test protocol (n = 10)
Number of subjects: 20
Study: 9219143

Group type: EXPERIMENTAL
Intervention: Inpatient detoxification for cocaine withdrawal
Number of subjects: 0
Study: 1767541

Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy (sPTX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total parathyroidectomy and autotransplantation (PTX + AT)
Number of subjects: 40
Study: 7036283

Group type: EXPERIMENTAL
Intervention: 30 mg poly A‐poly U i.v. once a week for 6 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 29203151

Group type: EXPERIMENTAL
Intervention: ADV6209 (2mg/ml oral solution of midazolam containing cyclodextrin)
Number of subjects: 49
Study: 27183932

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 1888

Group type: COMPARATOR
Intervention: General education students
Number of subjects: 1888
Study: 23950550

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 22851406

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study: 20415574

Group type: EXPERIMENTAL
Intervention: Early ART (within 72 hours after CM diagnosis)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Delayed ART (after 10 weeks of treatment with fluconazole alone)
Number of subjects: 54
Study: 18711184

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Paclitaxel (GT)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 529
Study: 16779159

Group type: EXPERIMENTAL
Intervention: Digital pen and paper system
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional pens
Number of subjects: 21
Study: 12351537

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) patch administered the day before embryo transfer and continued until pregnancy test results or menstruation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 10078577

Group type: EXPERIMENTAL
Intervention: Water-gymnastics
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 258
Study: 7781399

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone preoperatively or postoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative or postoperative RT
Number of subjects: 0

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and RT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality of RT and chemotherapy
Number of subjects: 0
Study: 2111239

Group type: EXPERIMENTAL
Intervention: Insulin treatment for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 6108779

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg + Morphine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg + Morphine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg and 4 mg
Number of subjects: 0
Study: 6653648

Group type: EXPERIMENTAL
Intervention: Diazoxide 150 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Labetalol 50 mg
Number of subjects: 25
Study: 30915467

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) provided daily during pregnancy and first 6 months postpartum, and to infants from age 6 to 18 months.
Number of subjects: 775

Group type: COMPARATOR
Intervention: Non-LNS group received daily iron and folic acid or multiple micronutrients during pregnancy and first 6 months postpartum, with no infant supplementation.
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: LNS group among children with reliable responses.
Number of subjects: 775

Group type: COMPARATOR
Intervention: Non-LNS group among children with reliable responses.
Number of subjects: 775